Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
UAB offers MRI-US image fusion technique for prostate cancer detection

UAB offers MRI-US image fusion technique for prostate cancer detection

The latest advancement in prostate cancer detection is magnetic resonance imaging and ultrasound fusion-guided biopsy, which offers benefits for both patient and physician. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
CMS publishes draft coverage decision for Decipher Prostate Cancer Classifier

CMS publishes draft coverage decision for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. [More]
New combination therapy shows promise in treating prostate cancer

New combination therapy shows promise in treating prostate cancer

Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness. [More]
Astellas partners with Men's Health Network and USA Rugby to offer free health screenings

Astellas partners with Men's Health Network and USA Rugby to offer free health screenings

Astellas Pharma US, Inc., in partnership with USA Rugby and national patient advocacy organization Men's Health Network, will offer free health screenings and education around the historic match between the USA Eagles and the world champion New Zealand All Blacks rugby teams. [More]
Chesapeake Urology offers revolutionary biopsy system for detection, diagnosis of prostate cancer

Chesapeake Urology offers revolutionary biopsy system for detection, diagnosis of prostate cancer

Chesapeake Urology Associates ("Chesapeake"), continually on the forefront of clinical and technological innovation, offers a state-of-the-art prostate cancer diagnostic, which "fuses" detailed MRI scans with live, real-time ultrasound images of the prostate. [More]
Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers. [More]
UCSF researcher awarded Jim Lafferty Memorial Research Grant for early detection of prostate cancer

UCSF researcher awarded Jim Lafferty Memorial Research Grant for early detection of prostate cancer

ZERO - The End of Prostate Cancer recently awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, M.D., M.P.H., of UC San Francisco for the purpose of researching new and improved methods for early detection of prostate cancer. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
Hormone loss may cause colon cancer, say Thomas Jefferson University researchers

Hormone loss may cause colon cancer, say Thomas Jefferson University researchers

Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer. [More]
RNA molecules in tissue, urine samples can detect prostate cancer

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals. [More]
VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, today announced that further data analysis from its colorectal cancer study was presented today at the 9th International Conference of Anticancer Research, being held October 6-10, 2014 in Sithonia, Greece. [More]
Stiff rise in generic drug prices prompts probe by members of Congress

Stiff rise in generic drug prices prompts probe by members of Congress

The prices have increased by more than 1,000 percent for some of the drugs. In other news about treatments, a study finds robotic surgery may not improve care for ovarian problems and the National Cancer Institute laments that insurers' concerns about cost are keeping some patients from proton therapy trials. [More]
U-M researchers propose new ways to fight sepsis

U-M researchers propose new ways to fight sepsis

A decade ago, America's health care community took on heart attacks with gusto, harnessing the power of research and data to make sure that every patient got the best possible care. [More]
Testosterone therapy raises risk of prostate tumors in rats

Testosterone therapy raises risk of prostate tumors in rats

A researcher who found that testosterone raised the risk of prostate tumors and exacerbated the effects of carcinogenic chemical exposure in rats is urging caution in prescribing testosterone therapy to men who have not been diagnosed with hypogonadism, according to a new study published in the Endocrine Society's journal Endocrinology. [More]
Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer. [More]
Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Early detection of cancers on the horizon with supersensitive nanodevice

Early detection of cancers on the horizon with supersensitive nanodevice

Extremely early detection of cancers and other diseases is on the horizon with a supersensitive nanodevice being developed at The University of Alabama in Huntsville in collaboration with The Joint School of Nanoscience and Nanoengineering in Greensboro, NC. [More]
Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. [More]